Can this service be used for osteoarthritis models?

Yes. We can adapt the screening approach for OA models or customize it based on the inflammatory profile and disease stage.

Is negative selection necessary?

While optional, we strongly recommend it to eliminate peptides that bind skin, muscle, or liver nonspecifically.

What is the typical timeline?

Projects usually take 10–14 weeks, depending on the model and number of enrichment rounds.

Can Creative Biolabs help prepare peptide-conjugated delivery vectors?

Yes. We offer downstream services for conjugation to nanoparticles, liposomes, or imaging agents.

Can this service support grant-funded academic studies?

Absolutely. We routinely support both academic and industry clients with flexible budgets and deliverables tailored for publication or translational use.

Human Synovium Targeting In Vivo Phage Library Screening Service

Introduction Our Services Workflow Platform Advantages Deliverables FAQ Resources

Introduction

The synovial membrane plays a pivotal role in joint homeostasis and is centrally involved in the pathogenesis of inflammatory and degenerative joint diseases, such as rheumatoid arthritis (RA) and osteoarthritis (OA). However, selective delivery of therapeutics to the human synovium remains a significant translational challenge. Creative Biolabs offers a dedicated human synovium targeting in vivo phage library screening service designed to identify peptides or ligands that preferentially accumulate in synovial tissues within a living system.

Leveraging our expertise in disease modeling and vascularized tissue targeting, Creative Biolabs enables researchers to uncover functionally active binding motifs that operate under physiological conditions—bridging the gap between discovery and clinical utility.

Our Services

Creative Biolabs' comprehensive screening service is tailored for synovium-targeted ligand discovery and includes:

Use of high-diversity peptide libraries (>10⁹ unique phage clones)

Ensures a comprehensive representation of possible binding motifs for synovial tissue targets.
Increases the likelihood of identifying novel peptides with high specificity and affinity.
Libraries may be linear, cyclic, or constrained, depending on project design

Human synovium xenograft or humanized mouse joint model establishment

Enables physiological relevance by incorporating human synovial components in vivo.
Provides a controlled environment to study peptide interactions under inflammatory or disease conditions.
Ensures reproducibility and comparability between experimental rounds.

Systemic phage library administration under defined circulation time

Allows phages to distribute naturally and bind to target tissue receptors in vivo.
Circulation duration is optimized to balance tissue exposure and systemic clearance.
Controlled injection conditions minimize stress and variability in targeting outcomes.

Targeted recovery from implanted or diseased synovial tissue

Post-circulation, the target tissue is dissected to recover bound phages.
This step isolates clones that interact specifically with synovial cell markers or disease-related epitopes.
Proper tissue handling preserves the integrity of bound phage populations.

Negative selection steps (e.g., muscle, skin, liver) to reduce off-target binders

Phages binding nonspecifically to common tissue components are eliminated.
Enhances signal-to-noise ratio for identifying synovium-specific binders.
Reduces cross-reactivity and improves the selectivity of enriched clones.

Iterative in vivo biopanning rounds for enriched specificity

Typically involves 3–5 selection cycles with amplification after each recovery.
Gradually enriches for high-affinity, synovium-targeting clones.
Ensures reproducible convergence toward consensus binding motifs.

High-throughput sequencing of selected clones

Reveals enriched peptide sequences from the selected phage pool.
Allows statistical comparison between rounds to identify dominant motifs.
Enables rapid data analysis for downstream validation candidate selection.

Bioinformatics clustering, motif analysis, and lead identification

Groups related peptide sequences to uncover structural or functional similarities.
Identifies conserved residues that contribute to binding activity.
Provides insights into potential molecular targets or binding domains.

Optional synthesis and validation of top peptide candidates

Synthetic peptides are produced for confirmatory binding assays.
Validation includes in vitro binding, imaging, or affinity quantification tests.
Results confirm functional relevance and practical application potential in targeting studies.

Whether you're studying inflammatory joint pathology, synovial fibrosis, or seeking to deliver targeted biologics, we are here to provide tailored support based on your research goals.

Workflow

Creative Biolabs applies a streamlined yet customizable workflow to ensure high-quality outcomes:

Library Selection

Choose from commercial or proprietary peptide display libraries (cyclic, linear, or random).
Model Setup

Use of immunodeficient mice engrafted with human synovium, or arthritic mouse models, depending on study design.
Phage Library Injection

Controlled intravenous administration, with circulation optimized to reach inflamed synovial microenvironments.
Tissue Harvesting and Phage Recovery

Collection of xenografted synovium or target joint tissue, with optional parallel harvesting of off-target tissues.
Enrichment Rounds

2–4 rounds of in vivo selection to isolate and amplify synovium-homing phage.
Sequence Analysis

NGS or Sanger sequencing followed by clustering, redundancy removal, and frequency mapping.
Optional Validation

Synthesize and fluorescently label candidates to confirm selective accumulation via ex vivo imaging or histology.

Creative Biolabs also offers consultation and reporting support to align screening outcomes with downstream therapeutic development or academic publication.

Phage-based Library Screening Platform

Creative Biolabs' platform is built on the principle that biological realism drives functional discovery. Unlike in vitro screening systems that miss critical elements of the physiological microenvironment, Creative Biolabs' in vivo phage display platform selects ligands under the full complexity of living organisms—blood flow, immune surveillance, interstitial pressure, tissue-specific endothelial barriers, and the synovial extracellular matrix.

For human synovium targeting, this approach is especially important. The synovium's fenestrated capillaries, dense ECM, and inflammation-modified permeability represent unique challenges. Creative Biolabs' platform ensures that only ligands capable of overcoming these hurdles are selected, yielding truly functional leads for drug delivery, diagnostics, or imaging.

Advantages

Synovium-Focused Expertise

Creative Biolabs has developed and validated human synovium-engrafted models for highly relevant selection conditions.

Selective Targeting Approach

Negative selection steps remove clones that bind commonly to off-target tissues.

Customized Screening Design

We tailor protocols based on the disease model, inflammation state, and targeting requirements.

Transparent Communication

Creative Biolabs provides milestone-based updates, with dedicated project managers for each campaign.

For specific pricing and solutions, please reach out anytime.

Deliverables

At the conclusion of the project, Creative Biolabs will deliver:

Final report including model details, selection protocols, and sequencing data
List of high-affinity, synovium-homing peptide sequences
Bioinformatic analysis of candidate motifs and enrichment patterns
Amplified phage stocks of enriched pools or individual clones
Optional: Fluorescently labeled peptides or synthesized leads
Optional: Validation data from imaging or histology studies

Additional deliverables such as vector conjugation, targeting peptide optimization, or animal imaging studies are available upon request.

If our services can benefit your research project, please contact Creative Biolabs. Our specialist team is ready to tailor a proposal to help advance your project's progress.

FAQ

Q: Can this service be used for osteoarthritis models?
A: Yes. We can adapt the screening approach for OA models or customize it based on the inflammatory profile and disease stage.
Q: Is negative selection necessary?
A: While optional, we strongly recommend it to eliminate peptides that bind skin, muscle, or liver nonspecifically.
Q: What is the typical timeline?
A: Projects usually take 10–14 weeks, depending on the model and number of enrichment rounds.
Q: Can Creative Biolabs help prepare peptide-conjugated delivery vectors?
A: Yes. We offer downstream services for conjugation to nanoparticles, liposomes, or imaging agents.
Q: Can this service support grant-funded academic studies?
A: Absolutely. We routinely support both academic and industry clients with flexible budgets and deliverables tailored for publication or translational use.